MSLE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 2.33%, SMA50 30.53%, SMA200 79.39%). The stock’s 14-day RSI is 63.49 (firm momentum), while the ATR of 0.71 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.72% below its high and over 157.46% above its low. Average 10-day trading volume of 37.89 thousand shares is below the 3-month average of 53.51 thousand, indicating normal recent market interest.

Satellos Bioscience Inc. generated EPS of -$1.57 over the past year. Five-year average earnings growth is 5.62%. Wall Street analysts project EPS growth of 6.14% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $11.00. The high target offers 135.9% upside. The low target suggests 12.82% downside. The mean target is $16.60. This offers 70.26% upside. Satellos Bioscience Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 9.73%. The prior quarter beat by 3.92%. Over the last six quarters, Apple has recorded several small beats. These include 11.14% in November 14, 2025.

Satellos Bioscience Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.81. This means the shares are trading above this model’s fair value.

currently trading near 52-week highs band. Valuation shows Satellos Bioscience Inc. trading at a premium to the broader market with a P/E of -5.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.60, suggesting 70.26% upside. Our AI forecast model points to short-term weakness (-3.69% over two weeks), a medium-term fall (-30.05% over three months), and a longer-term loss (-81.23% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Satellos Bioscience Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.69%, with price expected at $9.39 by September 24, 2026, within a range of $9.08 to $9.66 3-Month Outlook: Projected fall of -30.05%, reaching $6.82 by December 09, 2026, with a range of $6.54 to $7.24. 1-Year Outlook: Projected loss of -81.23%, with price at $1.83 by September 10, 2027, within a range of $1.37 to $2.05.

Satellos Bioscience Inc. (NASDAQ:MSLE) closed at $9.75 USD, losing -$0.30 (-2.99%) from the previous close of $10.05. The stock is currently mid-range between its 52-week high and low $5.30 and $13.39. With a market capitalization of about $12.56 million, Satellos Bioscience Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 54.54 thousand shares, volume is running light vs its 52-week average. Headquartered in Toronto, ON, Satellos Bioscience Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Francis Gleeson, the company employs approximately 18 people and listed since August 03, 2012. Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.

Satellos Bioscience Inc. trades at a P/E ratio of -5.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.49 trading at moderately above to book value. The P/FCF stands at -0.45, also above market averages.